Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Receives $48.40 Average PT from Analysts

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) has been assigned a consensus rating of “Buy” from the seven research firms that are covering the company, Marketbeat reports. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $48.40.

AAPG has been the topic of several recent research reports. Lucid Cap Mkts raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, December 15th. Piper Sandler started coverage on Ascentage Pharma Group International in a research report on Wednesday, November 5th. They set an “overweight” rating and a $48.00 price target on the stock. Rodman & Renshaw assumed coverage on Ascentage Pharma Group International in a report on Tuesday, January 13th. They issued a “buy” rating and a $48.00 price objective for the company. Truist Financial set a $51.00 target price on Ascentage Pharma Group International in a research report on Monday, November 24th. Finally, BTIG Research assumed coverage on Ascentage Pharma Group International in a research report on Monday, November 10th. They issued a “buy” rating and a $50.00 price target on the stock.

Hedge Funds Weigh In On Ascentage Pharma Group International

Several hedge funds and other institutional investors have recently made changes to their positions in the company. UBS Group AG boosted its position in shares of Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after acquiring an additional 10,988 shares in the last quarter. XY Capital Ltd raised its position in Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after purchasing an additional 12,530 shares in the last quarter. Tema Etfs LLC bought a new stake in Ascentage Pharma Group International during the second quarter worth $610,000. Hsbc Holdings PLC acquired a new stake in shares of Ascentage Pharma Group International in the 2nd quarter valued at $391,000. Finally, Citadel Advisors LLC bought a new position in shares of Ascentage Pharma Group International in the 3rd quarter valued at $383,000.

Ascentage Pharma Group International Price Performance

NASDAQ:AAPG opened at $24.00 on Friday. Ascentage Pharma Group International has a 52 week low of $17.09 and a 52 week high of $48.45. The company has a quick ratio of 1.53, a current ratio of 1.54 and a debt-to-equity ratio of 1.31. The firm’s 50-day simple moving average is $27.17 and its 200 day simple moving average is $33.98.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.